Andrew Spaltenstein

Statistics

Publications

Citations

1.5K

H-Index

Active since

1993

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

Vertex Pharmaceuticals (United States)

GlaxoSmithKline (United Kingdom)

Burroughs Wellcome Fund

Andrew Spaltenstein is an author at Research Triangle Park Foundation specializing in medicinal chemistry, drug discovery, and antiviral pharmacology.

Publications per year

1993–2013

Publications

Polyacrylamides Bearing Pendant .alpha.-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza A Virus: Multivalency and Steric Stabilization of Particulate Biological Systems

Watson J. Lees, Andrew Spaltenstein, Jill Kingery-Wood et al. · Journal of Medicinal Chemistry · 1994 · 191 citations

Life Sciences, Immunology, Infectious Diseases +5

Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir

Eric S. Furfine, Christopher Baker, Michael Hale et al. · Antimicrobial Agents and Chemotherapy · 2004 · 98 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1

Kristjan S. Gudmundsson, Sharon Boggs, John G. Catalano et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 85 citations

Medicine, Medicinal Chemistry, Pharmacology +10

Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents

John F. Miller, Elizabeth M. Turner, Kristjan S. Gudmundsson et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 84 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385

John F. Miller, C. Webster Andrews, Michael Brieger et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–5 of 32